GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Third Harmonic Bio Inc (NAS:THRD) » Definitions » Equity-to-Asset

Third Harmonic Bio (Third Harmonic Bio) Equity-to-Asset : 0.97 (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Third Harmonic Bio Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Third Harmonic Bio's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $269.09 Mil. Third Harmonic Bio's Total Assets for the quarter that ended in Dec. 2023 was $277.71 Mil.

The historical rank and industry rank for Third Harmonic Bio's Equity-to-Asset or its related term are showing as below:

THRD' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.18   Med: 0.3   Max: 0.97
Current: 0.97

During the past 4 years, the highest Equity to Asset Ratio of Third Harmonic Bio was 0.97. The lowest was -2.18. And the median was 0.30.

THRD's Equity-to-Asset is ranked better than
98.02% of 1566 companies
in the Biotechnology industry
Industry Median: 0.66 vs THRD: 0.97

Third Harmonic Bio Equity-to-Asset Historical Data

The historical data trend for Third Harmonic Bio's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Third Harmonic Bio Equity-to-Asset Chart

Third Harmonic Bio Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
-2.18 -0.36 0.97 0.97

Third Harmonic Bio Quarterly Data
Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.97 0.97 0.97 0.97 0.97

Competitive Comparison of Third Harmonic Bio's Equity-to-Asset

For the Biotechnology subindustry, Third Harmonic Bio's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Third Harmonic Bio's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Third Harmonic Bio's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Third Harmonic Bio's Equity-to-Asset falls into.



Third Harmonic Bio Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Third Harmonic Bio's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=269.085/277.711
=

Third Harmonic Bio's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=269.085/277.711
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Third Harmonic Bio  (NAS:THRD) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Third Harmonic Bio Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Third Harmonic Bio's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Third Harmonic Bio (Third Harmonic Bio) Business Description

Traded in Other Exchanges
N/A
Address
1700 Montgomery Street, Suite 210, San Francisco, CA, USA, 94111
Third Harmonic Bio Inc is a clinical-stage company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases.. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival.
Executives
Julie Person officer: Chief Administrative Officer C/O THIRD HARMONIC BIO, INC., 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Edward R. Conner officer: Chief Medical Officer 501 CANAL BLVD., POINT RICHMOND TECH CENTER, RICHMOND CA 94804
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd. other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Biotechnology Value Trading Fund Os Lp other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
David P Bonita director, 10 percent owner C/O ORBIMED ADVISORS LLC, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Atlas Venture Fund Xi, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139